Celcuity (CELC) Cash from Investing Activities (2016 - 2025)
Celcuity's (CELC) quarterly Cash from Investing Activities came in at $103.4 million in Q4 2025, up 175.32% YoY from $37.6 million in Q4 2024, and up 140.14% on a QoQ basis from -$257.6 million in Q3 2025.
Analysis
Celcuity (CELC) Cash from Investing Activities (2016 - 2025) Analysis & Trends
Celcuity (CELC) has 10 years of Cash from Investing Activities data on file, last reported at $103.4 million in Q4 2025.
- Quarterly Cash from Investing Activities rose 175.32% year-over-year to $103.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$64.1 million (down 1.61% YoY) and the FY2025 annual result came in at -$64.1 million, down 1.61% from the prior year.
- Cash from Investing Activities improved to $103.4 million in Q4 2025, from -$257.6 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $103.4 million in Q4 2025 to a low of -$257.6 million in Q3 2025.
- A 5-year average of -$13.8 million and a median of -$10787.0 in 2021 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2022 — Cash from Investing Activities plunged 1448587.69% — and 2023, when it jumped 188046.29%.
- Tracing CELC's Cash from Investing Activities over 5 years: stood at -$9939.0 in 2021, then sank by 1448587.69% to -$144.0 million in 2022, then surged by 71.37% to -$41.2 million in 2023, then jumped by 191.12% to $37.6 million in 2024, then jumped by 175.32% to $103.4 million in 2025.
- The last three Cash from Investing Activities figures came in at $103.4 million (Q4 2025), -$257.6 million (Q3 2025), and $65.9 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Celcuity | 5.25 Bn | 5.25 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 103.41 Mn |
| Sep 30, 2025 | -257.61 Mn |
| Jun 30, 2025 | 65.86 Mn |
| Mar 31, 2025 | 24.26 Mn |
| Dec 31, 2024 | 37.56 Mn |
| Sep 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | -106.07 Mn |
| Mar 31, 2024 | 3.54 Mn |
| Dec 31, 2023 | -41.22 Mn |
| Sep 30, 2023 | 6.25 Mn |
| Jun 30, 2023 | 8.09 Mn |
| Mar 31, 2023 | 21.87 Mn |
| Dec 31, 2022 | -143.99 Mn |
| Sep 30, 2022 | -12,103.00 |
| Jun 30, 2022 | -22,986.00 |
| Mar 31, 2022 | -11,635.00 |
| Dec 31, 2021 | -9,939.00 |
| Sep 30, 2021 | -14,062.00 |
| Jun 30, 2021 | -26,972.00 |
| Mar 31, 2021 | -30,425.00 |